WHO Classification of Tumours of Haematopoetic and Lymphoid Tissue, International Agency for Research on Cancer (IARC), 2008. ,
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances, Blood Reviews, vol.30, issue.6, pp.453-459, 2016. ,
DOI : 10.1016/j.blre.2016.06.001
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, The Lancet, vol.365, issue.9464, pp.1054-1061, 2005. ,
DOI : 10.1016/S0140-6736(05)74230-6
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.suppl. 1, pp.1144-1148, 2005. ,
DOI : 10.1182/blood-2002-09-2839
in Myeloproliferative Disorders, New England Journal of Medicine, vol.352, issue.17, pp.1779-1790, 2005. ,
DOI : 10.1056/NEJMoa051113
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, pp.387-397, 2005. ,
On the molecular origins of the chronic myeloproliferative disorders: it all makes sense, Blood, vol.105, issue.11, pp.4187-4190, 2005. ,
DOI : 10.1182/blood-2005-03-1287
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera, Leukemia, vol.365, issue.9, 2007. ,
DOI : 10.1016/S0140-6736(05)71142-9
Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis, pp.459-468, 2007. ,
DOI : 10.1056/NEJMoa065202
Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation, Clinica Chimica Acta, vol.408, issue.1-2, pp.39-44, 2009. ,
DOI : 10.1016/j.cca.2009.07.002
Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2V617F mutant allele detection, BMC Cancer, vol.35, issue.1, p.206, 2013. ,
DOI : 10.1093/nar/gkm671
URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-13-206?site=bmccancer.biomedcentral.com
V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory, American Journal of Clinical Pathology, vol.132, issue.5, pp.713-721, 2009. ,
DOI : 10.1038/sj.leu.2404955
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014. ,
DOI : 10.1182/blood-2013-11-537167
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms, Leukemia, vol.9, issue.7, pp.1407-1413, 2014. ,
DOI : 10.1136/jcp.55.11.862
Presence of calreticulin mutations in JAK2-negative polycythemia vera, Blood, vol.124, issue.26, pp.3964-3966, 2014. ,
DOI : 10.1182/blood-2014-06-583161
Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms, Annals of Laboratory Medicine, vol.35, issue.1, pp.22-27, 2015. ,
DOI : 10.3343/alm.2015.35.1.22
URL : http://europepmc.org/articles/pmc4272961?pdf=render
CALR, JAK2, and MPL Mutation Profiles in Patients With Four Different Subtypes of Myeloproliferative Neoplasms: Primary Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera, and Myeloproliferative Neoplasm, Unclassifiable, American Journal of Clinical Pathology, vol.143, issue.5, pp.635-644, 2015. ,
DOI : 10.1309/AJCPUAAC16LIWZMM
The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia, Turkish Journal of Hematology, vol.33, issue.3, pp.180-186, 2016. ,
DOI : 10.4274/tjh.2015.0220
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis, Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis, pp.3735-3743, 2007. ,
DOI : 10.1182/blood-2007-05-089003
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3476, 2006. ,
DOI : 10.1182/blood-2006-04-018879
Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis, American Journal of Hematology, vol.86, issue.8, pp.701-702, 2011. ,
DOI : 10.1002/ajh.22058
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort, Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by highresolution melting analysis, pp.141-149, 2008. ,
DOI : 10.1182/blood-2008-01-131664
allelic burden, Leukemia & Lymphoma, vol.57, issue.6, pp.1429-1435, 2016. ,
DOI : 10.1038/sj.leu.2405097
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms, Haematologica, vol.96, issue.4, pp.607-611, 2011. ,
DOI : 10.3324/haematol.2010.034793
Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients, PLoS ONE, vol.5, issue.1, p.8893, 2010. ,
DOI : 10.1371/journal.pone.0008893.t001
Germline Variation in Cancer-Susceptibility Genes in a Healthy, Ancestrally Diverse Cohort: Implications for Individual Genome Sequencing, PLoS ONE, vol.265, issue.4, p.94554 ,
DOI : 10.1371/journal.pone.0094554.s002
(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis, Exp Hematol, vol.37, pp.21186-1193, 2009. ,
Clinical correlates ofJAK2V617F allele burden in essential thrombocythemia, Cancer, vol.130, issue.11, pp.2279-2284, 2007. ,
DOI : 10.1016/S0140-6736(05)71142-9
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.22663/pdf
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera, Leukemia, vol.21, issue.9, pp.2074-2075, 2007. ,
DOI : 10.1038/sj.leu.2404500
URL : http://www.nature.com/leu/journal/v21/n9/pdf/2404724a.pdf
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal, Leukemia, vol.21, issue.7, pp.1299-1307, 2008. ,
DOI : 10.1182/blood-2007-01-066985
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia, Myeloproliferative Disorders Research C: Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia, pp.41-48, 2008. ,
DOI : 10.3324/haematol.11653
V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm, Blood Research, vol.48, issue.2, pp.128-132, 2013. ,
DOI : 10.5045/br.2013.48.2.128
mutation in Philadelphia-negative chronic myeloproliferative neoplasms, International Journal of Laboratory Hematology, vol.40, issue.6, pp.766-773, 2015. ,
DOI : 10.1093/nar/gks203
Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?, Applied Immunohistochemistry & Molecular Morphology, vol.24, issue.8, pp.589-594, 2016. ,
DOI : 10.1097/PAI.0000000000000228
URL : https://academic.oup.com/ajcp/article-pdf/138/suppl_2/A357/18136290/ajcpath138-167.pdf
The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms, Thrombosis Research, vol.135, issue.2, pp.272-280, 2015. ,
DOI : 10.1016/j.thromres.2014.11.006
JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm, Zhonghua Xue Ye Xue Za Zhi, vol.36, pp.191-195, 2015. ,